CLL Monthly Minutes
The combination of acalabrutinib, venetoclax, and obinutuzumab has been shown to be an active regimen in previously untreated patients with CLL. Read More ›
During the first 13 months of the pandemic, COVID-19 continued to result in high hospitalization rates among patients with CLL. Read More ›
Identifying the risk factors for infection may allow preventive measures to be taken to protect patients. Read More ›
Oral targeted therapies have revolutionized treatment for patients with CLL but ensuring that they are taken as prescribed is crucial to achieving optimal outcomes. Read More ›
Copay assistance coupons and copay adjustment programs put patients in the middle of healthcare cost-saving measures. Read More ›
Currently, many effective, well-tolerated treatments exist, with high expectations for new drugs and regimens to be developed and approved in the near future. Read More ›
A literature review found a set of physical, psychological, social, and spiritual topics that could be used to better educate patients throughout their CLL treatment journey. Read More ›
COVID-19 vaccination is generally safe for immunocompromised patients, including those with CLL, although the efficacy is substantially lower than in healthy individuals. Read More ›
Cell-based assays and animal data suggest that ZN-d5 may be a tolerable and effective treatment for patients with leukemias and lymphomas. Read More ›
The first head-to-head trial of these drugs shows comparable efficacy with a better cardiovascular safety profile for acalabrutinib. Read More ›